Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company, today announced the pricing of its previously announced "best efforts" underwritten public offering of 1,449,275 shares of its common stock at a price to the public of $3.45 per share. Hoth expects to receive aggregate gross proceeds of approximately $5 million from the offering, before deducting the underwriting discount and estimated offering expenses. The offering is expected to close on or about March 26, 2020, subject to customary closing conditions.

Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering. Roth Capital Partners is acting as a financial advisor to the Company.

Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent the COVID-19 virus, working capital, sales and marketing activities, and general and administrative matters.

About Hoth Therapeutics Incorporated

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.